Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center, Martinistrasse 52, 20246 Hamburg-Eppendorf, Germany.
Eur J Dermatol. 2013 Apr 1;23(2):212-7. doi: 10.1684/ejd.2013.1988.
Psoriasis vulgaris is a common disease that follows a chronic course. So far, few studies have addressed outcome methods which evaluate the benefits of drugs and medical devices by measuring patient preferences.
Assessment of patients' outcomes using the "Patient benefit index" (PBI), a validated goal attainment scaling tool, in the treatment of psoriasis. Data were obtained within an epidemiological study in 2,009 patients with psoriasis vulgaris and/or psoriatic arthritis.
Cross-sectional study in 133 nationwide German dermatological practices and hospital departments. The following were recorded a) in the doctors' questionnaire--previous treatments and diseases, clinical characteristics and psoriasis area and severity index (PASI), b) in the patients' questionnaire--quality of life (LQ), patient-relevant therapeutic benefits and satisfaction with care.
On average, patients achieved a total PBI of 2.5±1.1. 86.7% of patients showed a more than minimum benefit (PBI>1). Patients treated with biologicals had a higher benefit (mean PBI 3.0) than patients in other groups (e.g. PBI 2.6 in systemics).
PBI values indicate that systemic agents and biologics are of high therapeutic benefit to the vast majority of patients. The development of the PBI has enabled a decisive step to be taken in the area of scientifically-based outcome assessments.
寻常型银屑病是一种常见的慢性疾病。迄今为止，很少有研究通过衡量患者偏好来评估药物和医疗器械的获益，从而选择合适的疗效评估方法。
使用“患者获益指数（PBI）”评估寻常型银屑病和/或银屑病关节炎患者的治疗结局。该指数是一种经过验证的目标达成评分工具，数据来自于 2009 例寻常型银屑病和/或银屑病关节炎患者的流行病学研究。
在全国 133 家皮肤科诊所和医院进行横断面研究。医生问卷中记录了以下内容：既往治疗和疾病、临床特征和银屑病面积和严重程度指数（PASI）；患者问卷中记录了生活质量（LQ）、患者相关的治疗获益和对护理的满意度。
患者的平均总 PBI 为 2.5±1.1。86.7%的患者获益程度超过最低标准（PBI＞1）。与其他治疗组相比（如系统治疗组的 PBI 为 2.6），接受生物制剂治疗的患者获益更高（平均 PBI 为 3.0）。
PBI 值表明，大多数患者使用全身性药物和生物制剂治疗具有较高的获益。PBI 的开发在基于科学的疗效评估领域迈出了重要一步。
